Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Pharmacological Treatment of Neuropathic Pain in Children

Author(s): Lisa M. Einhorn, Jonathan Hudon and Pablo Ingelmo*

Volume 22, Issue 1, 2024

Published on: 04 August, 2023

Page: [38 - 52] Pages: 15

DOI: 10.2174/1570159X21666230804110858

Price: $65

Abstract

The International Association for the Study of Pain (IASP) defines neuropathic pain as pain caused by a lesion or disease of the somatosensory nervous system. It is characterized as a clinical condition in which diagnostic studies reveal an underlying cause of an abnormality in the peripheral or central nervous system. Many common causes of neuropathic pain in adults are rare in children. The purpose of this focused narrative review is, to 1) provide an overview of neuropathic pain in children, 2) highlight unique considerations related to the diagnosis and mechanisms of neuropathic pain in children, and 3) perform a comprehensive analysis of the pharmacological treatments available. We emphasize that data for routine use of pharmacological agents in children with neuropathic pain are largely inferred from adult literature with little research performed on pediatric populations, yet have clear evidence of harms to pediatric patients. Based on these findings, we propose risk mitigation strategies such as utilizing topical treatments whenever possible, assessing pain phenotyping to guide drug class choice, and considering pharmaceuticals in the broader context of the multidisciplinary treatment of pediatric pain. Furthermore, we highlight important directions for future research on pediatric neuropathic pain treatment.

« Previous Next »
Graphical Abstract

[1]
Pain, N. International Association for the Study of Pain., Available from: https://www.iasp-pain.org/resources/terminology/#Neuro-pathicpain
[2]
Jensen, T.S.; Baron, R.; Haanpää, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.C.; Treede, R.D. A new definition of neuropathic pain. Pain, 2011, 152(10), 2204-2205.
[http://dx.doi.org/10.1016/j.pain.2011.06.017] [PMID: 21764514]
[3]
Loeser, J.D. A new way of thinking about pains. Pain, 2022, 163(9), 1670-1674.
[http://dx.doi.org/10.1097/j.pain.0000000000002583] [PMID: 35984381]
[4]
Shraim, M.A.; Massé-Alarie, H.; Hodges, P.W. Methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: A systematic review. Pain, 2021, 162(4), 1007-1037.
[http://dx.doi.org/10.1097/j.pain.0000000000002113] [PMID: 33136983]
[5]
Howard, R.F.; Wiener, S.; Walker, S.M. Neuropathic pain in children. Arch. Dis. Child., 2014, 99(1), 84-89.
[http://dx.doi.org/10.1136/archdischild-2013-304208] [PMID: 24114955]
[6]
Ingelmo, P.M.; Fumagalli, R. Neuropathic pain in children. Minerva Anestesiol., 2004, 70(5), 393-398.
[PMID: 15181421]
[7]
Walker, S.M. Neuropathic pain in children: Steps towards improved recognition and management. EBioMedicine, 2020, 62, 103124.
[http://dx.doi.org/10.1016/j.ebiom.2020.103124] [PMID: 33248373]
[8]
Walco, G.A.; Dworkin, R.H.; Krane, E.J.; LeBel, A.A.; Treede, R.D. Neuropathic pain in children: Special considerations. Mayo Clin. Proc., 2010, 85(3), S33-S41.
[http://dx.doi.org/10.4065/mcp.2009.0647] [PMID: 20194147]
[9]
Konijnenberg, A.Y.; Uiterwaal, C.S.; Kimpen, J.L.; van der Hoeven, J.; Buitelaar, J.K.; de Graeff-Meeder, E.R. Children with unexplained chronic pain: Substantial impairment in everyday life. Arch. Dis. Child., 2005, 90(7), 680-686.
[http://dx.doi.org/10.1136/adc.2004.056820] [PMID: 15899922]
[10]
Friedrichsdorf, S.; Giordano, J.; Desai Dakoji, K.; Warmuth, A.; Daughtry, C.; Schulz, C. Chronic pain in children and adolescents: Diagnosis and treatment of primary pain disorders in head, abdomen, muscles and joints. Children (Basel), 2016, 3(4), 42.
[http://dx.doi.org/10.3390/children3040042] [PMID: 27973405]
[11]
Baron, R.; Tölle, T.R.; Gockel, U.; Brosz, M.; Freynhagen, R. A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain, 2009, 146(1), 34-40.
[http://dx.doi.org/10.1016/j.pain.2009.06.001] [PMID: 19592166]
[12]
Gottrup, H.; Kristensen, A.D.; Bach, F.W.; Jensen, T.S. Aftersensations in experimental and clinical hypersensitivity. Pain, 2003, 103(1), 57-64.
[http://dx.doi.org/10.1016/S0304-3959(02)00415-3] [PMID: 12749959]
[13]
Katz, J.; Melzack, R. Referred sensations in chronic pain patients. Pain, 1987, 28(1), 51-59.
[http://dx.doi.org/10.1016/0304-3959(87)91059-1] [PMID: 3822494]
[14]
Anghelescu, D.L.; Steen, B.D.; Wu, H.; Wu, J.; Daw, N.C.; Rao, B.N.; Neel, M.D.; Navid, F. Prospective study of neuropathic pain after definitive surgery for extremity osteosarcoma in a pediatric population. Pediatr. Blood Cancer, 2017, 64(3), e26162.
[http://dx.doi.org/10.1002/pbc.26162] [PMID: 27573717]
[15]
Yeung, K.K.; Engle, L.; Rabel, A.; Adamson, K.; Schwellnus, H.; Evans, C. It just feels weird!: A qualitative study of how children aged 10-18 years describe neuropathic pain. Disabil. Rehabil., 2017, 39(17), 1695-1702.
[http://dx.doi.org/10.1080/09638288.2016.1207107] [PMID: 27684213]
[16]
Voepel-Lewis, T.; Merkel, S.; Tait, A.R.; Trzcinka, A.; Malviya, S. The reliability and validity of the Face, Legs, Activity, Cry, Consolability observational tool as a measure of pain in children with cognitive impairment. Anesth. Analg., 2002, 95(5), 1224-1229.
[http://dx.doi.org/10.1097/00000539-200211000-00020] [PMID: 12401598]
[17]
McGrath, P.J.; Walco, G.A.; Turk, D.C.; Dworkin, R.H.; Brown, M.T.; Davidson, K.; Eccleston, C.; Finley, G.A.; Goldschneider, K.; Haverkos, L.; Hertz, S.H.; Ljungman, G.; Palermo, T.; Rappaport, B.A.; Rhodes, T.; Schechter, N.; Scott, J.; Sethna, N.; Svensson, O.K.; Stinson, J.; von Baeyer, C.L.; Walker, L.; Weisman, S.; White, R.E.; Zajicek, A.; Zeltzer, L. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J. Pain, 2008, 9(9), 771-783.
[http://dx.doi.org/10.1016/j.jpain.2008.04.007] [PMID: 18562251]
[18]
Romanò, C.L.; Romanò, D.; Lacerenza, M. Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: A systematic review. Pain Res. Treat., 2012, 2012, 1-8.
[http://dx.doi.org/10.1155/2012/154781] [PMID: 22619711]
[19]
Finnerup, N.B.; Kuner, R.; Jensen, T.S. Neuropathic pain: From mechanisms to treatment. Physiol. Rev., 2021, 101(1), 259-301.
[http://dx.doi.org/10.1152/physrev.00045.2019] [PMID: 32584191]
[20]
Bennett, M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain, 2001, 92(1), 147-157.
[http://dx.doi.org/10.1016/S0304-3959(00)00482-6] [PMID: 11323136]
[21]
Bouhassira, D.; Attal, N.; Alchaar, H.; Boureau, F.; Brochet, B.; Bruxelle, J.; Cunin, G.; Fermanian, J.; Ginies, P.; Grun-Overdyking, A.; Jafari-Schluep, H.; Lantéri-Minet, M.; Laurent, B.; Mick, G.; Serrie, A.; Valade, D.; Vicaut, E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, 2005, 114(1), 29-36.
[http://dx.doi.org/10.1016/j.pain.2004.12.010] [PMID: 15733628]
[22]
Krause, S.J.; Backonja, M.M. Development of a neuropathic pain questionnaire. Clin. J. Pain, 2003, 19(5), 306-314.
[http://dx.doi.org/10.1097/00002508-200309000-00004] [PMID: 12966256]
[23]
Finnerup, N.B.; Haroutounian, S.; Kamerman, P.; Baron, R.; Bennett, D.L.H.; Bouhassira, D.; Cruccu, G.; Freeman, R.; Hansson, P.; Nurmikko, T.; Raja, S.N.; Rice, A.S.C.; Serra, J.; Smith, B.H.; Treede, R.D.; Jensen, T.S. Neuropathic pain: An updated grading system for research and clinical practice. Pain, 2016, 157(8), 1599-1606.
[http://dx.doi.org/10.1097/j.pain.0000000000000492] [PMID: 27115670]
[24]
Treede, R.D.; Jensen, T.S.; Campbell, J.N.; Cruccu, G.; Dostrovsky, J.O.; Griffin, J.W.; Hansson, P.; Hughes, R.; Nurmikko, T.; Serra, J. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology, 2008, 70(18), 1630-1635.
[http://dx.doi.org/10.1212/01.wnl.0000282763.29778.59] [PMID: 18003941]
[25]
Bouhassira, D.; Attal, N. Diagnosis and assessment of neuropathic pain: The saga of clinical tools. Pain, 2011, 152(3), S74-S83.
[http://dx.doi.org/10.1016/j.pain.2010.11.027] [PMID: 21185120]
[26]
Rolke, R.; Baron, R.; Maier, C.; Tölle, T.R.; Treede, D.R.; Beyer, A.; Binder, A.; Birbaumer, N.; Birklein, F.; Bötefür, I.C.; Braune, S.; Flor, H.; Huge, V.; Klug, R.; Landwehrmeyer, G.B.; Magerl, W.; Maihöfner, C.; Rolko, C.; Schaub, C.; Scherens, A.; Sprenger, T.; Valet, M.; Wasserka, B. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values. Pain, 2006, 123(3), 231-243.
[http://dx.doi.org/10.1016/j.pain.2006.01.041] [PMID: 16697110]
[27]
Blankenburg, M.; Boekens, H.; Hechler, T.; Maier, C.; Krumova, E.; Scherens, A.; Magerl, W.; Aksu, F.; Zernikow, B. Reference values for quantitative sensory testing in children and adolescents: Developmental and gender differences of somatosensory perception. Pain, 2010, 149(1), 76-88.
[http://dx.doi.org/10.1016/j.pain.2010.01.011] [PMID: 20138430]
[28]
Ramaswamy, S.; Wodehouse, T. Conditioned pain modulation-A comprehensive review. Neurophysiol. Clin., 2021, 51(3), 197-208.
[http://dx.doi.org/10.1016/j.neucli.2020.11.002] [PMID: 33334645]
[29]
Bruneau, A.; Carrié, S.; Moscaritolo, L.; Ingelmo, P. Mechanism-based pharmacological treatment for chronic non-cancer pain in adolescents: Current approaches and future directions. Paediatr. Drugs, 2022, 24(6), 573-583.
[http://dx.doi.org/10.1007/s40272-022-00534-x] [PMID: 36053398]
[30]
Bruneau, A.; Ferland, C.E.; Pérez-Medina-Carballo, R.; Somaini, M.; Mohamed, N.; Curatolo, M.; Ouellet, J.A.; Ingelmo, P. Association between the use of quantitative sensory testing and conditioned pain modulation and the prescription of medication and interventional procedures in children with chronic pain conditions. Children (Basel), 2022, 9(8), 1157.
[http://dx.doi.org/10.3390/children9081157] [PMID: 36010048]
[31]
Colloca, L.; Ludman, T.; Bouhassira, D.; Baron, R.; Dickenson, A.H.; Yarnitsky, D.; Freeman, R.; Truini, A.; Attal, N.; Finnerup, N.B.; Eccleston, C.; Kalso, E.; Bennett, D.L.; Dworkin, R.H.; Raja, S.N. Neuropathic pain. Nat. Rev. Dis. Primers, 2017, 3(1), 17002.
[http://dx.doi.org/10.1038/nrdp.2017.2] [PMID: 28205574]
[32]
Kocot-Kępska, M.; Zajączkowska, R.; Mika, J.; Wordliczek, J.; Dobrogowski, J.; Przeklasa-Muszyńska, A. Peripheral mechanisms of neuropathic pain-the role of neuronal and non-neuronal interactions and their implications for topical treatment of neuropathic pain. Pharmaceuticals (Basel), 2021, 14(2), 77.
[http://dx.doi.org/10.3390/ph14020077] [PMID: 33498496]
[33]
Burma, N.E.; Leduc-Pessah, H.; Fan, C.Y.; Trang, T. Animal models of chronic pain: Advances and challenges for clinical translation. J. Neurosci. Res., 2017, 95(6), 1242-1256.
[http://dx.doi.org/10.1002/jnr.23768] [PMID: 27376591]
[34]
Jaggi, A.S.; Jain, V.; Singh, N. Animal models of neuropathic pain. Fundam. Clin. Pharmacol., 2011, 25(1), 1-28.
[http://dx.doi.org/10.1111/j.1472-8206.2009.00801.x] [PMID: 20030738]
[35]
Decosterd, I.; Woolf, C.J. Spared nerve injury: An animal model of persistent peripheral neuropathic pain. Pain, 2000, 87(2), 149-158.
[http://dx.doi.org/10.1016/S0304-3959(00)00276-1] [PMID: 10924808]
[36]
Bennett, G.J.; Xie, Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain, 1988, 33(1), 87-107.
[http://dx.doi.org/10.1016/0304-3959(88)90209-6] [PMID: 2837713]
[37]
Gilron, I.; Baron, R.; Jensen, T. Neuropathic pain: Principles of diagnosis and treatment. Mayo Clin. Proc., 2015, 90(4), 532-545.
[http://dx.doi.org/10.1016/j.mayocp.2015.01.018] [PMID: 25841257]
[38]
Ririe, D.G.; Eisenach, J.C. Age-dependent responses to nerve injury-induced mechanical allodynia. Anesthesiology, 2006, 104(2), 344-350.
[http://dx.doi.org/10.1097/00000542-200602000-00021] [PMID: 16436855]
[39]
Lee, D.H.; Chung, J.M. Neuropathic pain in neonatal rats. Neurosci. Lett., 1996, 209(2), 140-142.
[http://dx.doi.org/10.1016/0304-3940(96)12623-9] [PMID: 8762002]
[40]
Howard, R.F.; Walker, S.M.; Mota, M.P.; Fitzgerald, M. The ontogeny of neuropathic pain: Postnatal onset of mechanical allodynia in rat spared nerve injury (SNI) and chronic constriction injury (CCI) models. Pain, 2005, 115(3), 382-389.
[http://dx.doi.org/10.1016/j.pain.2005.03.016] [PMID: 15911165]
[41]
Fitzgerald, M.; McKelvey, R. Nerve injury and neuropathic pain-A question of age. Exp. Neurol., 2016, 275(Pt 2), 296-302.
[http://dx.doi.org/10.1016/j.expneurol.2015.07.013] [PMID: 26220898]
[42]
Anand, P.; Birch, R. Restoration of sensory function and lack of long-term chronic pain syndromes after brachial plexus injury in human neonates. Brain, 2002, 125(1), 113-122.
[http://dx.doi.org/10.1093/brain/awf017] [PMID: 11834597]
[43]
Atherton, D.D.; Taherzadeh, O.; Elliot, D.; Anand, P. Age-dependent development of chronic neuropathic pain, allodynia and sensory recovery after upper limb nerve injury in children. J. Hand Surg. Eur. Vol., 2008, 33(2), 186-191.
[http://dx.doi.org/10.1177/1753193408087029] [PMID: 18443061]
[44]
Vega-Avelaira, D.; McKelvey, R.; Hathway, G.; Fitzgerald, M. The emergence of adolescent onset pain hypersensitivity following neonatal nerve injury. Mol. Pain, 2012, 8, 1744-8069-8-30.
[http://dx.doi.org/10.1186/1744-8069-8-30] [PMID: 22531549]
[45]
McKelvey, R.; Berta, T.; Old, E.; Ji, R.R.; Fitzgerald, M. Neuropathic pain is constitutively suppressed in early life by anti-inflammatory neuroimmune regulation. J. Neurosci., 2015, 35(2), 457-466.
[http://dx.doi.org/10.1523/JNEUROSCI.2315-14.2015] [PMID: 25589741]
[46]
Hermann, C.; Hohmeister, J.; Demirakça, S.; Zohsel, K.; Flor, H. Long-term alteration of pain sensitivity in school-aged children with early pain experiences. Pain, 2006, 125(3), 278-285.
[http://dx.doi.org/10.1016/j.pain.2006.08.026] [PMID: 17011707]
[47]
Beggs, S.; Currie, G.; Salter, M.W.; Fitzgerald, M.; Walker, S.M. Priming of adult pain responses by neonatal pain experience: maintenance by central neuroimmune activity. Brain, 2012, 135(2), 404-417.
[http://dx.doi.org/10.1093/brain/awr288] [PMID: 22102650]
[48]
Ren, K.; Anseloni, V.; Zou, S.P.; Wade, B.E.; Novikova, I.S.; Ennis, M.; Traub, J.R.; Gold, S.M.; Dubner, R.; Lidow, S.M. Characterization of basal and re-inflammation-associated long-term alteration in pain responsivity following short-lasting neonatal local inflamatory insult. Pain, 2004, 110(3), 588-596.
[http://dx.doi.org/10.1016/j.pain.2004.04.006] [PMID: 15288399]
[49]
Taddio, A.; Goldbach, M.; Ipp, M.; Stevens, B.; Koren, G. Effect of neonatal circumcision on pain responses during vaccination in boys. Lancet, 1995, 345(8945), 291-292.
[http://dx.doi.org/10.1016/S0140-6736(95)90278-3] [PMID: 7837863]
[50]
Scheffel, J.; Regen, T.; Van Rossum, D.; Seifert, S.; Ribes, S.; Nau, R.; Parsa, R.; Harris, R.A.; Boddeke, H.W.G.M.; Chuang, H.N.; Pukrop, T.; Wessels, J.T.; Jürgens, T.; Merkler, D.; Brück, W.; Schnaars, M.; Simons, M.; Kettenmann, H.; Hanisch, U.K. Toll-like receptor activation reveals developmental reorganization and unmasks responder subsets of microglia. Glia, 2012, 60(12), 1930-1943.
[http://dx.doi.org/10.1002/glia.22409] [PMID: 22911652]
[51]
Melzack, R.; Israel, R.; Lacroix, R.; Schultz, G. Phantom limbs in people with congenital limb deficiency or amputation in early childhood. Brain, 1997, 120(9), 1603-1620.
[http://dx.doi.org/10.1093/brain/120.9.1603] [PMID: 9313643]
[52]
Cooper, T.E.; Wiffen, P.J.; Heathcote, L.C.; Clinch, J.; Howard, R.; Krane, E.; Lord, S.M.; Sethna, N.; Schechter, N.; Wood, C. Antiepileptic drugs for chronic non-cancer pain in children and adolescents. Cochrane Libr., 2017, 8(8), CD012536.
[http://dx.doi.org/10.1002/14651858.CD012536.pub2] [PMID: 28779491]
[53]
Cooper, T.E.; Heathcote, L.C.; Clinch, J.; Gold, J.I.; Howard, R.; Lord, S.M.; Schechter, N.; Wood, C.; Wiffen, P.J. Antidepressants for chronic non-cancer pain in children and adolescents. Cochrane Database Syst. Rev., 2017, 8(8), CD012535.
[PMID: 28779487]
[54]
Cooper, T.E.; Fisher, E.; Gray, A.L.; Krane, E.; Sethna, N.; van Tilburg, M.A.; Zernikow, B.; Wiffen, P.J. Opioids for chronic non-cancer pain in children and adolescents. Cochrane Database Syst. Rev., 2017, 7(7), CD012538.
[PMID: 28745394]
[55]
Eccleston, C.; Fisher, E.; Cooper, T.E.; Grégoire, M.C.; Heathcote, L.C.; Krane, E.; Lord, S.M.; Sethna, N.F.; Anderson, A.K.; Anderson, B.; Clinch, J.; Gray, A.L.; Gold, J.I.; Howard, R.F.; Ljungman, G.; Moore, R.A.; Schechter, N.; Wiffen, P.J.; Wilkinson, N.M.R.; Williams, D.G.; Wood, C.; van Tilburg, M.A.L.; Zernikow, B. Pharmacological interventions for chronic pain in children: An overview of systematic reviews. Pain, 2019, 160(8), 1698-1707.
[http://dx.doi.org/10.1097/j.pain.0000000000001609] [PMID: 31335640]
[56]
World Health Organization. Guidelines on the management of chronic pain in children., 2020. Available from: https://www.who.int/publications/i/item/9789240017870
[57]
Taylor, C.P. Mechanisms of action of gabapentin. Rev. Neurol. (Paris), 1997, 153(Suppl. 1), S39-S45.
[PMID: 9686247]
[58]
Abdi, S.; Lee, D.H.; Chung, J.M. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth. Analg., 1998, 87(6), 1360-1366.
[http://dx.doi.org/10.1213/00000539-199812000-00027] [PMID: 9842827]
[59]
Donado, C.; Nedeljkovic, K.; Wangnamthip, S.; Solodiuk, J.C.; Bourgeois, F.T.; Berde, C.B. Trends in gabapentin and pregabalin prescribing in a tertiary pediatric medical center. Hosp. Pediatr., 2021, 11(8), 909-914.
[http://dx.doi.org/10.1542/hpeds.2020-003582] [PMID: 34257145]
[60]
Akkurt, H.E. Gümüş H.; Göksu, H.; Odabaşı Ö.F.; Yılmaz, H. Gabapentin treatment for neuropathic pain in a child with sciatic nerve injury. Case Rep. Med., 2015, 2015, 1-3.
[http://dx.doi.org/10.1155/2015/873157] [PMID: 26346828]
[61]
Saroyan, J.M.; Winfree, C.J.; Schechter, W.S.; Roye, D.; Gold, A.P. Sciatic neuropathy after lower-extremity trauma: successful treatment of an uncommon pain and disability syndrome in an adolescent. Am. J. Phys. Med. Rehabil., 2007, 86(7), 597-600.
[http://dx.doi.org/10.1097/PHM.0b013e31806dbdd2] [PMID: 17581294]
[62]
Ries, M.; Mengel, E.; Kutschke, G.; Kim, K.S.; Birklein, F.; Krummenauer, F.; Beck, M. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J. Inherit. Metab. Dis., 2003, 26(4), 413-414.
[http://dx.doi.org/10.1023/A:1025127723729] [PMID: 12971431]
[63]
Rusy, L.M.; Troshynski, T.J.; Weisman, S.J. Gabapentin in phantom limb pain management in children and young adults: report of seven cases. J. Pain Symptom Manage., 2001, 21(1), 78-82.
[http://dx.doi.org/10.1016/S0885-3924(00)00243-8] [PMID: 11223317]
[64]
Kaul, I.; Amin, A.; Rosenberg, M.; Rosenberg, L.; Meyer, W.J., III Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review. Burns, 2018, 44(2), 414-422.
[http://dx.doi.org/10.1016/j.burns.2017.07.018] [PMID: 28822592]
[65]
Vondracek, P.; Oslejskova, H.; Kepak, T.; Mazanek, P.; Sterba, J.; Rysava, M.; Gal, P. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur. J. Paediatr. Neurol., 2009, 13(4), 332-336.
[http://dx.doi.org/10.1016/j.ejpn.2008.06.011] [PMID: 18774740]
[66]
Anghelescu, D.L.; Faughnan, L.G.; Jeha, S.; Relling, M.V.; Hinds, P.S.; Sandlund, J.T.; Cheng, C.; Pei, D.; Hankins, G.; Pauley, J.L.; Pui, C.H. Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer, 2011, 57(7), 1147-1153.
[http://dx.doi.org/10.1002/pbc.23039] [PMID: 21319291]
[67]
Anghelescu, D.L.; Tesney, J.M.; Jeha, S.; Wright, B.B.; Trujillo, L.; Sandlund, J.T.; Pauley, J.; Cheng, C.; Pei, D.; Pui, C.H. Prospective randomized trial of interventions for vincristine‐related neuropathic pain. Pediatr. Blood Cancer, 2020, 67(9), e28539.
[http://dx.doi.org/10.1002/pbc.28539] [PMID: 32618122]
[68]
Anghelescu, D.L.; Tesney, J.M. Neuropathic pain in pediatric oncology: A clinical decision algorithm. Paediatr. Drugs, 2019, 21(2), 59-70.
[http://dx.doi.org/10.1007/s40272-018-00324-4] [PMID: 30761460]
[69]
Friedrichsdorf, S.J.; Nugent, A.P. Management of neuropathic pain in children with cancer. Curr. Opin. Support. Palliat. Care, 2013, 7(2), 131-138.
[http://dx.doi.org/10.1097/SPC.0b013e3283615ebe] [PMID: 23635878]
[70]
Coluzzi, F.; Rocco, M.; Green Gladden, R.; Persiani, P.; Thur, L.A.; Milano, F. Pain management in childhood leukemia: Diagnosis and available analgesic treatments. Cancers (Basel), 2020, 12(12), 3671.
[http://dx.doi.org/10.3390/cancers12123671] [PMID: 33297484]
[71]
Brown, S.; Johnston, B.; Amaria, K.; Watkins, J.; Campbell, F.; Pehora, C.; McGrath, P. A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. Scand. J. Pain, 2016, 13(1), 156-163.
[http://dx.doi.org/10.1016/j.sjpain.2016.05.039] [PMID: 28850523]
[72]
Molero, Y.; Larsson, H.; D’Onofrio, B.M.; Sharp, D.J.; Fazel, S. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: Population based cohort study in Sweden. BMJ, 2019, 365, l2147.
[http://dx.doi.org/10.1136/bmj.l2147] [PMID: 31189556]
[73]
M Peckham, A.; Ananickal, M.; Sclar, D. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag. Healthc. Policy, 2018, 11, 109-116.
[http://dx.doi.org/10.2147/RMHP.S168504] [PMID: 30154674]
[74]
Li, D.; Huang, S.; Wang, X.; Yang, L.; Song, T. Efficacy and adverse reactions of perampanel in the treatment of epilepsy in children. Front. Neurol., 2022, 13, 924057.
[http://dx.doi.org/10.3389/fneur.2022.924057] [PMID: 35968281]
[75]
De Caro, C.; Cristiano, C.; Avagliano, C.; Cuozzo, M.; La Rana, G.; Aviello, G.; De Sarro, G.; Calignano, A.; Russo, E.; Russo, R. Analgesic and anti-inflammatory effects of perampanel in acute and chronic pain models in mice: interaction with the cannabinergic system. Front. Pharmacol., 2021, 11, 620221.
[http://dx.doi.org/10.3389/fphar.2020.620221] [PMID: 33597883]
[76]
Khangura, R.K.; Bali, A.; Kaur, G.; Singh, N.; Jaggi, A.S. Neuropathic pain attenuating effects of perampanel in an experimental model of chronic constriction injury in rats. Biomed. Pharmacother., 2017, 94, 557-563.
[http://dx.doi.org/10.1016/j.biopha.2017.07.137] [PMID: 28780471]
[77]
Hara, K.; Haranishi, Y.; Terada, T. Intrathecally administered perampanel alleviates neuropathic and inflammatory pain in rats. Eur. J. Pharmacol., 2020, 872, 172949.
[http://dx.doi.org/10.1016/j.ejphar.2020.172949] [PMID: 31991141]
[78]
Chang, M.C.; Park, D. Effectiveness of perampanel in managing chronic pain caused by the complex regional pain syndrome. Medicine (Baltimore), 2021, 100(48), e27791.
[http://dx.doi.org/10.1097/MD.0000000000027791] [PMID: 35049177]
[79]
Finnerup, N.B.; Attal, N.; Haroutounian, S.; McNicol, E.; Baron, R.; Dworkin, R.H.; Gilron, I.; Haanpää, M.; Hansson, P.; Jensen, T.S.; Kamerman, P.R.; Lund, K.; Moore, A.; Raja, S.N.; Rice, A.S.C.; Rowbotham, M.; Sena, E.; Siddall, P.; Smith, B.H.; Wallace, M. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol., 2015, 14(2), 162-173.
[http://dx.doi.org/10.1016/S1474-4422(14)70251-0] [PMID: 25575710]
[80]
National Institute for Health and Care Excellence. Neuropathic pain in adults: pharacological management in non-specialist settings., Available from: https://www.nice.org.uk/guidance/cg173/chapter/Recommendations
[81]
Bates, D.; Schultheis, B.C.; Hanes, M.C.; Jolly, S.M.; Chakravarthy, K.V.; Deer, T.R.; Levy, R.M.; Hunter, C.W. A comprehensive algorithm for management of neuropathic pain. Pain Med., 2019, 20(Suppl. 1), S2-S12.
[http://dx.doi.org/10.1093/pm/pnz075] [PMID: 31152178]
[82]
Moulin, D.E.; Boulanger, A.; Clark, A.J.; Clarke, H.; Dao, T.; Finley, G.A.; Furlan, A.; Gilron, I.; Gordon, A.; Morley-Forster, P.K.; Sessle, B.J.; Squire, P.; Stinson, J.; Taenzer, P.; Velly, A.; Ware, M.A.; Weinberg, E.L.; Williamson, O.D. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Res. Manag., 2014, 19(6), 328-335.
[http://dx.doi.org/10.1155/2014/754693] [PMID: 25479151]
[83]
Windsor, R.B.; Sierra, M.; Zappitelli, M.; McDaniel, M. Beyond Amitriptyline: A pediatric and adolescent oriented narrative review of the analgesic properties of psychotropic medications for the treatment of complex pain and headache disorders. Children (Basel), 2020, 7(12), 268.
[http://dx.doi.org/10.3390/children7120268] [PMID: 33276542]
[84]
Jackson, K.C., II; St Onge, E.L. Antidepressant pharmacotherapy: Considerations for the pain clinician. Pain Pract., 2003, 3(2), 135-143.
[http://dx.doi.org/10.1046/j.1533-2500.2003.03020.x] [PMID: 17163912]
[85]
Saps, M.; Youssef, N.; Miranda, A.; Nurko, S.; Hyman, P.; Cocjin, J.; Di Lorenzo, C. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology, 2009, 137(4), 1261-1269.
[http://dx.doi.org/10.1053/j.gastro.2009.06.060] [PMID: 19596010]
[86]
de Bruijn, C.M.; Rexwinkel, R.; Gordon, M.; Benninga, M.; Tabbers, M.M. Antidepressants for functional abdominal pain disorders in children and adolescents. Cochrane Database Syst Rev., 2021, 2(2), CD008013.2.
[87]
Wilder, R.T.; Berde, C.B.; Wolohan, M.; Vieyra, M.A.; Masek, B.J.; Micheli, L.J. Reflex sympathetic dystrophy in children. Clinical characteristics and follow-up of seventy patients. J. Bone Joint Surg. Am., 1992, 74(6), 910-919.
[http://dx.doi.org/10.2106/00004623-199274060-00013] [PMID: 1634582]
[88]
Politei, J.M.; Bouhassira, D.; Germain, D.P.; Goizet, C.; Guerrero-Sola, A.; Hilz, M.J.; Hutton, E.J.; Karaa, A.; Liguori, R.; Üçeyler, N.; Zeltzer, L.K.; Burlina, A. Pain in fabry disease: Practical recommendations for diagnosis and treatment. CNS Neurosci. Ther., 2016, 22(7), 568-576.
[http://dx.doi.org/10.1111/cns.12542] [PMID: 27297686]
[89]
Moore, R.A.; Derry, S.; Aldington, D.; Cole, P.; Wiffen, P.J. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst. Rev., 2015, 2015(7), CD008242.
[PMID: 26146793]
[90]
Moore, R.A.; Derry, S.; Aldington, D.; Cole, P.; Wiffen, P.J. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev., 2012, 12, CD008242.
[PMID: 23235657]
[91]
Hearn, L.; Moore, R.A.; Derry, S.; Wiffen, P.J.; Phillips, T. Desipramine for neuropathic pain in adults. Cochrane Database Syst. Rev., 2014, 2014(9), CD011003.
[PMID: 25246131]
[92]
Dharmshaktu, P.; Tayal, V.; Kalra, B.S. Efficacy of antidepressants as analgesics: A review. J. Clin. Pharmacol., 2012, 52(1), 6-17.
[http://dx.doi.org/10.1177/0091270010394852] [PMID: 21415285]
[93]
Max, M.B.; Lynch, S.A.; Muir, J.; Shoaf, S.E.; Smoller, B.; Dubner, R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med., 1992, 326(19), 1250-1256.
[http://dx.doi.org/10.1056/NEJM199205073261904] [PMID: 1560801]
[94]
Lunn, M.P.; Hughes, R.A.; Wiffen, P.J. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2, 2014, 3(1), CD007115.
[http://dx.doi.org/10.1002/14651858.CD007115.pub3] [PMID: 24385423]
[95]
Okuma, K.; Shiraishi, K.; Kanai, Y.; Nakagawa, K. Improvement in quality of life by using duloxetine for chemotherapy-induced peripheral neuropathy (CIPN): A case report. Support. Care Cancer, 2016, 24(11), 4483-4485.
[http://dx.doi.org/10.1007/s00520-016-3349-1] [PMID: 27448406]
[96]
Meng, J.; Zhang, Q.; Yang, C.; Xiao, L.; Xue, Z.; Zhu, J. Duloxetine, a balanced serotonin-norepinephrine reuptake inhibitor, improves painful chemotherapy-induced peripheral neuropathy by inhibiting activation of p38 MAPK and NF-κB. Front. Pharmacol., 2019, 10, 365.
[http://dx.doi.org/10.3389/fphar.2019.00365] [PMID: 31024320]
[97]
Meighen, K.G. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J. Child Adolesc. Psychopharmacol., 2007, 17(1), 121-127.
[http://dx.doi.org/10.1089/cap.2006.0042] [PMID: 17343560]
[98]
Desarkar, P.; Das, A.; Sinha, V.K. Duloxetine for childhood depression with pain and dissociative symptoms. Eur. Child Adolesc. Psychiatry, 2006, 15(8), 496-499.
[http://dx.doi.org/10.1007/s00787-006-0553-4] [PMID: 16732464]
[99]
Kachko, L.; Ben Ami, S.; Liberman, A.; Birk, E.; Kronenberg, S. Duloxetine contributing to a successful multimodal treatment program for peripheral femoral neuropathy and comorbid ‘reactive depression’ in an adolescent. Pain Res. Manag., 2011, 16(6), 457-459.
[http://dx.doi.org/10.1155/2011/164984] [PMID: 22184557]
[100]
Burghardt, K.J.; Thomas, S.T.; Tutag-Lehr, V. Off-label use of duloxetine for pediatric neuropathic pain. Ment. Health Clin., 2015, 5(6), 277-283.
[http://dx.doi.org/10.9740/mhc.2015.11.277]
[101]
Baig, M.U.; Madden, K.; Moody, K. Hyponatremia with antidepressant: A rare side effect from duloxetine in a child with acute leukemia. J. Palliat. Med., 2022, 25(12), 1884-1887.
[http://dx.doi.org/10.1089/jpm.2021.0526] [PMID: 35537479]
[102]
Semenchuk, M.R.; Davis, B. Efficacy of sustained-release bupropion in neuropathic pain: An open-label study. Clin. J. Pain, 2000, 16(1), 6-11.
[http://dx.doi.org/10.1097/00002508-200003000-00002] [PMID: 10741812]
[103]
Semenchuk, M.R.; Sherman, S.; Davis, B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology, 2001, 57(9), 1583-1588.
[http://dx.doi.org/10.1212/WNL.57.9.1583] [PMID: 11706096]
[104]
Valentino, R.J.; Volkow, N.D. Untangling the complexity of opioid receptor function. Neuropsychopharmacology, 2018, 43(13), 2514-2520.
[http://dx.doi.org/10.1038/s41386-018-0225-3] [PMID: 30250308]
[105]
Windsor, R.B.; Tham, S.W.; Adams, T.L.; Anderson, A. The use of opioids for treatment of pediatric neuropathic pain. Clin. J. Pain, 2019, 35(6), 509-514.
[http://dx.doi.org/10.1097/AJP.0000000000000712] [PMID: 30985402]
[106]
McNicol, E.D.; Midbari, A.; Eisenberg, E. Opioids for neuropathic pain. Cochrane Database Syst. Rev., 2013, 2013(8), CD006146.
[PMID: 23986501]
[107]
Duehmke, R.M.; Derry, S.; Wiffen, P.J.; Bell, R.F.; Aldington, D.; Moore, R.A. Tramadol for neuropathic pain in adults. Cochrane Database Syst. Rev., 2017, 6(6), CD003726.
[PMID: 28616956]
[108]
FDA Drug Safety Communication. FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children., Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020281s039lbl.pdf
[109]
Finkel, J.C.; Goldberg, J.; Rosenburg, R.; Ariyawansa, J.; Sun, T.; Ochs-Ross, R.; Zannikos, P.; Zhang, L.; Etropolski, M. First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. J. Pain Res., 2019, 12, 1925-1936.
[http://dx.doi.org/10.2147/JPR.S197348] [PMID: 31303784]
[110]
Muse, D.; Tarau, E.; Lefeber, C.; Sohns, M.; Brett, M.; Goldberg, J.; Rosenburg, R. Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients. J. Pain Res., 2019, 12, 1777-1790.
[http://dx.doi.org/10.2147/JPR.S197039] [PMID: 31213888]
[111]
Johnson, P.N.; Boyles, K.A.; Miller, J.L. Selection of the initial methadone regimen for the management of iatrogenic opioid abstinence syndrome in critically ill children. Pharmacotherapy, 2012, 32(2), 148-157.
[http://dx.doi.org/10.1002/PHAR.1001] [PMID: 22392424]
[112]
Tobias, J.D. Methadone: Applications in pediatric anesthesiology and critical care medicine. J. Anesth., 2021, 35(1), 130-141.
[http://dx.doi.org/10.1007/s00540-020-02887-4] [PMID: 33432486]
[113]
Dervan, L.A.; Yaghmai, B.; Watson, R.S.; Wolf, F.M. The use of methadone to facilitate opioid weaning in pediatric critical care patients: A systematic review of the literature and meta‐analysis. Paediatr. Anaesth., 2017, 27(3), 228-239.
[http://dx.doi.org/10.1111/pan.13056] [PMID: 28109052]
[114]
Ye, J.; Myung, K.; Packiasabapathy, S.; Yu, J.S.; Jacobson, J.E.; Whittaker, S.C.; Castelluccio, P.; Drayton Jackson, M.; Sadhasivam, S. Methadone-based multimodal analgesia provides the best-in-class acute surgical pain control and functional outcomes with lower opioid use following major posterior fusion surgery in adolescents with idiopathic scoliosis. Pediatr. Qual. Saf., 2020, 5(4), e336.
[http://dx.doi.org/10.1097/pq9.0000000000000336] [PMID: 32766507]
[115]
Boisvert-Plante, V.; Poulin-Harnois, C.; Ingelmo, P.; Einhorn, L.M. What we know and what we don’t know about the perioperative use of methadone in children and adolescents. Paediatr. Anaesth., 2022.
[PMID: 36281540]
[116]
Friedrichsdorf, S.J.; Kang, T.I. The management of pain in children with life-limiting illnesses. Pediatr. Clin. North Am., 2007, 54(5), 645-672. x.
[http://dx.doi.org/10.1016/j.pcl.2007.07.007] [PMID: 17933616]
[117]
Anghelescu, D.L.; Faughnan, L.G.; Hankins, G.M.; Ward, D.A.; Oakes, L.L. Methadone use in children and young adults at a cancer center: A retrospective study. J. Opioid. Manag., 2011, 7(5), 353-361.
[http://dx.doi.org/10.5055/jom.2011.0076] [PMID: 22165034]
[118]
Hall, E.A.; Sauer, H.E.; Habashy, C.; Anghelescu, D.L. Methadone for cancer pain in pediatric end-of-life care. Am. J. Hosp. Palliat. Care, 2021, 38(8), 914-919.
[http://dx.doi.org/10.1177/1049909120963641] [PMID: 33000633]
[119]
Habashy, C.; Springer, E.; Hall, E.A.; Anghelescu, D.L. Methadone for pain management in children with cancer. Paediatr. Drugs, 2018, 20(5), 409-416.
[http://dx.doi.org/10.1007/s40272-018-0304-2] [PMID: 30047027]
[120]
Vo, T.; Rice, A.S.C.; Dworkin, R.H. Non-steroidal anti-inflammatory drugs for neuropathic pain: How do we explain continued widespread use? Pain, 2009, 143(3), 169-171.
[http://dx.doi.org/10.1016/j.pain.2009.03.013] [PMID: 19362418]
[121]
Moore, R.A.; Chi, C.C.; Wiffen, P.J.; Derry, S.; Rice, A.S. Oral nonsteroidal anti‐inflammatory drugs for neuropathic pain. Cochrane Database Syst. Rev., 2015, 2015(10), CD010902.
[http://dx.doi.org/10.1002/14651858.CD010902.pub2] [PMID: 26436601]
[122]
Zamproni, L.N.; Ribeiro, R.T.; Cardeal, M. Treatment of recurrent painful ophthalmoplegic neuropathy: A case where pregabalin was successfully employed. Case Rep. Neurol. Med., 2019, 2019, 1-5.
[http://dx.doi.org/10.1155/2019/9185603] [PMID: 30881712]
[123]
Myers, K.A.; Barmherzig, R.; Raj, N.R.; Berrahmoune, S.; Ingelmo, P.; Saint-Martin, C.; Khan, A.Q.; Kouri, M.; Morris, C.; Hershey, A.D.; Kacperski, J.; Kabbouche, M.A.; Mohamed, N.; Rao, R.R.; Lagman-Bartolome, A.M.; Gelfand, A.A.; Szperka, C.L.; Orr, S.L. The spectrum of indomethacin-responsive headaches in children and adolescents. Cephalalgia, 2022, 42(8), 793-797.
[http://dx.doi.org/10.1177/03331024221076483] [PMID: 35302385]
[124]
Hall, E.A.; Sauer, H.E.; Davis, M.S.; Anghelescu, D.L. Lidocaine infusions for pain management in pediatrics. Paediatr. Drugs, 2021, 23(4), 349-359.
[http://dx.doi.org/10.1007/s40272-021-00454-2] [PMID: 34036532]
[125]
Yang, X.; Wei, X.; Mu, Y.; Li, Q.; Liu, J. A review of the mechanism of the central analgesic effect of lidocaine. Medicine (Baltimore), 2020, 99(17), e19898.
[http://dx.doi.org/10.1097/MD.0000000000019898] [PMID: 32332666]
[126]
Sugimoto, M.; Uchida, I.; Mashimo, T. Local anaesthetics have different mechanisms and sites of action at the recombinant N-methyl-D-aspartate (NMDA) receptors. Br. J. Pharmacol., 2003, 138(5), 876-882.
[http://dx.doi.org/10.1038/sj.bjp.0705107] [PMID: 12642389]
[127]
Araujo, M.C.; Sinnott, C.J.; Strichartz, G.R. Multiple phases of relief from experimental mechanical allodynia by systemic lidocaine: responses to early and late infusions. Pain, 2003, 103(1), 21-29.
[http://dx.doi.org/10.1016/S0304-3959(02)00350-0] [PMID: 12749955]
[128]
Masic, D.; Liang, E.; Long, C.; Sterk, E.J.; Barbas, B.; Rech, M.A. Intravenous lidocaine for acute pain: A systematic review. Pharmacotherapy, 2018, 38(12), 1250-1259.
[http://dx.doi.org/10.1002/phar.2189] [PMID: 30303542]
[129]
Zhu, B.; Zhou, X.; Zhou, Q.; Wang, H.; Wang, S.; Luo, K. Intra-venous lidocaine to relieve neuropathic pain: A systematic review and meta-analysis. Front. Neurol., 2019, 10, 954.
[http://dx.doi.org/10.3389/fneur.2019.00954] [PMID: 31620064]
[130]
Kim, Y.C.; Castañeda, A.M.; Lee, C.; Jin, H.S.; Park, K.S.; Moon, J.Y. Efficacy and safety of lidocaine infusion treatment for neuropathic pain. Reg. Anesth. Pain Med., 2018, 43(4), 415-424.
[http://dx.doi.org/10.1097/AAP.0000000000000741] [PMID: 29381569]
[131]
van den Heuvel, S.A.S.; van der Wal, S.E.I.; Smedes, L.A.; Radema, S.A.; van Alfen, N.; Vissers, K.C.P.; Steegers, M.A.H. Intravenous lidocaine: Old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral neuropathy. Pain Res. Manag., 2017, 2017, 8053474.
[PMID: 28458593]
[132]
Hutson, P.; Backonja, M.; Knurr, H. Intravenous lidocaine for neuropathic pain: A retrospective analysis of tolerability and efficacy. Pain Med., 2015, 16(3), 531-536.
[http://dx.doi.org/10.1111/pme.12642] [PMID: 25530475]
[133]
Tremont-Lukats, I.W.; Hutson, P.R.; Backonja, M.M. A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain. Clin. J. Pain, 2006, 22(3), 266-271.
[http://dx.doi.org/10.1097/01.ajp.0000169673.57062.40] [PMID: 16514327]
[134]
Mooney, J.J.; Pagel, P.S.; Kundu, A. Safety, tolerability, and short-term efficacy of intravenous lidocaine infusions for the treatment of chronic pain in adolescents and young adults: A preliminary report. Pain Med., 2014, 15(5), 820-825.
[http://dx.doi.org/10.1111/pme.12333] [PMID: 24423053]
[135]
Puri, L.; Morgan, K.J.; Anghelescu, D.L. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease. Curr. Opin. Support. Palliat. Care, 2019, 13(4), 402-407.
[http://dx.doi.org/10.1097/SPC.0000000000000437] [PMID: 31157658]
[136]
Massey, G.V.; Pedigo, S.; Dunn, N.L.; Grossman, N.J.; Russell, E.C. Continuous lidocaine infusion for the relief of refractory malignant pain in a terminally ill pediatric cancer patient. J. Pediatr. Hematol. Oncol., 2002, 24(7), 566-568.
[http://dx.doi.org/10.1097/00043426-200210000-00015] [PMID: 12368697]
[137]
Gibbons, K.; DeMonbrun, A.; Beckman, E.J.; Keefer, P.; Wagner, D.; Stewart, M.; Saul, D.A.; Hakel, S.; Liu, M.; Niedner, M. Continuous lidocaine infusions to manage opioid-refractory pain in a series of cancer patients in a pediatric hospital. Pediatr. Blood Cancer, 2016, 63(7), 1168-1174.
[http://dx.doi.org/10.1002/pbc.25870] [PMID: 26784686]
[138]
Featherly, J.; Baxter Wojnowicz, S.; Steidl, K.; Burgess, J. Lidocaine for dinutuximab‐associated pain? A multicenter retrospective observational cohort study. Pediatr. Blood Cancer, 2022, 69(9), e29653.
[http://dx.doi.org/10.1002/pbc.29653] [PMID: 35441791]
[139]
Voltarelli, J.C.; Ahmed, H.; Paton, E.J.A.; Stracieri, A.B.P.L.; Holman, P.; Bashey, A.; Coutinho, M.; Simoes, B.P.; Ball, E.D.; Carrier, E. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion. Bone Marrow Transplant., 2001, 28(1), 97-99.
[http://dx.doi.org/10.1038/sj.bmt.1703080] [PMID: 11498752]
[140]
Wallace, M.S.; Lee, J.; Sorkin, L.; Dunn, J.S.; Yaksh, T.; Yu, A. Intravenous lidocaine. Anesth. Analg., 1997, 85(4), 794-796.
[http://dx.doi.org/10.1213/00000539-199710000-00014] [PMID: 9322457]
[141]
Kajiume, T.; Sera, Y.; Nakanuno, R.; Ogura, T.; Karakawa, S.; Kobayakawa, M.; Taguchi, S.; Oshita, K.; Kawaguchi, H.; Sato, T.; Kobayashi, M. Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. J. Palliat. Med., 2012, 15(6), 719-722.
[http://dx.doi.org/10.1089/jpm.2011.0097] [PMID: 22401313]
[142]
Finholt, D.A.; Stirt, J.A.; DiFazio, C.A.; Moscicki, J.C. Lidocaine pharmacokinetics in children during general anesthesia. Anesth. Analg., 1986, 65(3), 279-282.
[http://dx.doi.org/10.1213/00000539-198603000-00010] [PMID: 3954094]
[143]
Wallace, M.S.; Dyck, B.J.; Rossi, S.S.; Yaksh, T.L. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury. Pain, 1996, 66(1), 69-77.
[http://dx.doi.org/10.1016/0304-3959(96)02980-6] [PMID: 8857633]
[144]
Baron, R.; Allegri, M.; Correa-Illanes, G.; Hans, G.; Serpell, M.; Mick, G.; Mayoral, V. The 5% lidocaine-medicated plaster: Its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its use. Pain Ther., 2016, 5(2), 149-169.
[http://dx.doi.org/10.1007/s40122-016-0060-3] [PMID: 27822619]
[145]
Amato, F.; Duse, G.; Consoletti, L.; Lo Presti, C.; Firetto, V.; Ciliberto, G.; Parigi, L.A.; Palmieri, V.; Mazza, M. Efficacy and safety of 5% lidocaine-medicated plasters in localized pain with neuropathic and/or inflammatory characteristics: an observational, real-world study. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(18), 4228-4235.
[PMID: 29028074]
[146]
Palladini, M.; Boesl, I.; Koenig, S.; Buchheister, B.; Attal, N. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: Efficacy and safety results of a randomized, placebo-controlled trial. Curr. Med. Res. Opin., 2019, 35(5), 757-766.
[http://dx.doi.org/10.1080/03007995.2019.1565709] [PMID: 30614286]
[147]
Rousseau, V.; Morelle, M.; Arriuberge, C.; Darnis, S.; Chabaud, S.; Launay, V.; Thouvenin, S.; Roumenoff-Turcant, F.; Metzger, S.; Tourniaire, B.; Marec-Berard, P. Efficacy and tolerance of lidocaine 5% patches in neuropathic pain and pain related to vaso-occlusive sickle cell crises in children: A prospective multicenter clinical study. Pain Pract., 2018, 18(6), 788-797.
[http://dx.doi.org/10.1111/papr.12674] [PMID: 29266772]
[148]
Nayak, S.; Cunliffe, M. Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: Report of five cases. Paediatr. Anaesth., 2008, 18(6), 554-558.
[http://dx.doi.org/10.1111/j.1460-9592.2008.02491.x] [PMID: 18363625]
[149]
Rasolofo, J.; Poncelet, M.; Rousseau, V.; Marec-Berard, P. Analgesic efficacy of topical lidocaine for vaso-occlusive crisis in children with sickle cell disease. Arch. Pediatr., 2013, 20(7), 762-767.
[http://dx.doi.org/10.1016/j.arcped.2013.04.013] [PMID: 23731603]
[150]
Goddard, J.M.; Reaney, R.L. Lidocaine 5%-medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents. Br. J. Pain, 2018, 12(3), 189-193.
[http://dx.doi.org/10.1177/2049463718756431] [PMID: 30057764]
[151]
Hauer, J.; Houtrow, A.J.; Feudtner, C.; Klein, S.; Klick, J.; Linebarger, J.; Norwood, K.W., Jr; Adams, R.C.; Brei, T.J.; Davidson, L.F.; Davis, B.E.; Friedman, S.L.; Hyman, S.L.; Kuo, D.Z.; Noritz, G.H.; Yin, L.; Murphy, N.A. Pain assessment and treatment in children with significant impairment of the central nervous system. Pediatrics, 2017, 139(6), e20171002.
[http://dx.doi.org/10.1542/peds.2017-1002] [PMID: 28562301]
[152]
Burns, J.; Jackson, K.; Sheehy, K.A.; Finkel, J.C.; Quezado, Z.M. The use of dexmedetomidine in pediatric palliative care: A preliminary study. J. Palliat. Med., 2017, 20(7), 779-783.
[http://dx.doi.org/10.1089/jpm.2016.0419] [PMID: 28186850]
[153]
Ammerman, S.; Ryan, S.; Adelman, W.P.; Levy, S.; Ammerman, S.D.; Gonzalez, P.K.; Ryan, S.A.; Siqueira, L.M.; Smith, V.C.; Braverman, P.K.; Adelman, W.P.; Alderman, E.M.; Breuner, C.C.; Levine, D.A.; Marcell, A.V.; O’Brien, R.F. The impact of marijuana policies on youth: Clinical, research, and legal update. Pediatrics, 2015, 135(3), e769-e785.
[http://dx.doi.org/10.1542/peds.2014-4147] [PMID: 25624383]
[154]
Taylor, M.; Jakacki, R.; May, C.; Howrie, D.; Maurer, S. Ketamine PCA for treatment of end-of-life neuropathic pain in pediatrics. Am. J. Hosp. Palliat. Care, 2015, 32(8), 841-848.
[http://dx.doi.org/10.1177/1049909114543640] [PMID: 25028743]
[155]
Benini, F.; Congedi, S.; Giacomelli, L.; Papa, S.; Shah, A.; Milani, G. Refractory symptoms in paediatric palliative care: Can ketamine help? Drugs Context, 2021, 10, 1-9.
[http://dx.doi.org/10.7573/dic.2021-2-5] [PMID: 34104198]
[156]
Sheehy, K.A.; Muller, E.A.; Lippold, C.; Nouraie, M.; Finkel, J.C.; Quezado, Z.M.N. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: A longitudinal study. BMC Pediatr., 2015, 15(1), 198.
[http://dx.doi.org/10.1186/s12887-015-0515-4] [PMID: 26620833]
[157]
Derry, S.; Rice, A.S.; Cole, P.; Tan, T.; Moore, R.A. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2017, 1(1), CD007393.
[PMID: 28085183]
[158]
Glaros, A.K.; Callaghan, M.U.; Smith, W.R.; Zaidi, A.U. Targeting TRPV1 activity via high‐dose capsaicin in patients with sickle cell disease. eJHaem, 2022, 3(3), 653-659.
[http://dx.doi.org/10.1002/jha2.528] [PMID: 36051054]
[159]
Cavalli, E.; Mammana, S.; Nicoletti, F.; Bramanti, P.; Mazzon, E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int. J. Immunopathol. Pharmacol., 2019, 33.
[http://dx.doi.org/10.1177/2058738419838383] [PMID: 30900486]
[160]
Afshari, K.; Dehdashtian, A.; Haddadi, N.S.; Haj-Mirzaian, A.; Iranmehr, A.; Ebrahimi, M.A.; Tavangar, S.M.; Faghir-Ghanesefat, H.; Mohammadi, F.; Rahimi, N.; Javidan, A.N.; Dehpour, A.R. Anti-inflammatory effects of Metformin improve the neuropathic pain and locomotor activity in spinal cord injured rats: Introduction of an alternative therapy. Spinal Cord, 2018, 56(11), 1032-1041.
[http://dx.doi.org/10.1038/s41393-018-0168-x] [PMID: 29959433]
[161]
Vieira, G.; Cavalli, J.; Gonçalves, E.C.D.; Gonçalves, T.R.; Laurindo, L.R.; Cola, M.; Dutra, R.C. Effects of simvastatin beyond dyslipidemia: Exploring its antinociceptive action in an animal model of complex regional pain syndrome-type I. Front. Pharmacol., 2017, 8, 584.
[http://dx.doi.org/10.3389/fphar.2017.00584] [PMID: 28928655]
[162]
Kandhare, A.D.; Mukherjee, A.A.; Bodhankar, S.L. Neuroprotective effect of Azadirachta indica standardized extract in partial sciatic nerve injury in rats: Evidence from anti-inflammatory, antioxidant and anti-apoptotic studies. EXCLI J., 2017, 16, 546-565.
[PMID: 28694757]
[163]
Xia, Z-Y.; Xie, H-T.; Pan, X.; Zhao, B.; Liu, Z.G. Puerarin ameliorates allodynia and hyperalgesia in rats with peripheral nerve injury. Neural Regen. Res., 2018, 13(7), 1263-1268.
[http://dx.doi.org/10.4103/1673-5374.235074] [PMID: 30028336]
[164]
Forte, G.; Giuffrida, V.; Scuderi, A.; Pazzaglia, M. Future treatment of neuropathic pain in spinal cord injury: The challenges of nanomedicine, supplements or opportunities? Biomedicines, 2022, 10(6), 1373.
[http://dx.doi.org/10.3390/biomedicines10061373] [PMID: 35740395]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy